Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition